FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC By Ogkologos - June 24, 2026 100 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Breast02 study Source RELATED ARTICLESMORE FROM AUTHOR Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism EMA Recommends Extension of Indications for Ponatinib Associated with a New Pharmaceutical Form and a New Strength MOST POPULAR Experts Think Medical Detection Dogs Could Be Trained To Sniff Out... March 27, 2020 FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC June 24, 2026 Advancing Cancer Prevention: A Conversation with NCI’s Dr. Philip Castle July 20, 2021 Efficacy of Sintilimab in the Adjuvant Treatment for Patients with Resected,... January 26, 2024 Load more HOT NEWS Διαφημιστείτε For Early-Stage Lung Cancer, Study Identifies Potential New Biomarker, Treatment Target Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September More Treatment Options Emerging for Some Men with Metastatic Prostate Cancer
